Quick Answer
BeOne Medicines Ltd. reported Gross Profit of $4.67 billion for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +45.3% in Gross Profit from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $366.01 million | Q2 2023: $499.27 million | Q3 2023: $685.00 million | Q1 2024: $626.72 million | Q2 2024: $791.03 million | Q3 2024: $831.14 million | Q1 2025: $952.28 million | Q2 2025: $1.15 billion | Q3 2025: $1.22 billion.
- Over the full 5 years of available data (2021 to 2025), BeOne Medicines Ltd.'s Gross Profit has grown by 362.2%.
- Historical annual values: Fiscal year 2025: $4.67 billion | Fiscal year 2024: $3.22 billion | Fiscal year 2023: $2.08 billion | Fiscal year 2022: $1.13 billion | Fiscal year 2021: $1.01 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: